BNP Paribas Financial Markets Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

BNP Paribas Financial Markets grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 92.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,939 shares of the company’s stock after purchasing an additional 38,427 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.26% of Medpace worth $26,684,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Ashton Thomas Securities LLC purchased a new position in Medpace in the third quarter valued at $37,000. DT Investment Partners LLC acquired a new stake in shares of Medpace during the 2nd quarter valued at about $41,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace in the 3rd quarter valued at about $46,000. Ashton Thomas Private Wealth LLC acquired a new position in Medpace in the 2nd quarter worth about $52,000. Finally, International Assets Investment Management LLC purchased a new position in Medpace during the second quarter worth approximately $61,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 0.5 %

MEDP stock opened at $340.63 on Friday. The firm has a 50-day moving average of $337.82 and a two-hundred day moving average of $371.41. Medpace Holdings, Inc. has a 12 month low of $268.80 and a 12 month high of $459.77. The company has a market cap of $10.59 billion, a price-to-earnings ratio of 29.83, a PEG ratio of 1.88 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.22 earnings per share. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird boosted their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a report on Monday, November 25th. TD Cowen decreased their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Redburn Atlantic began coverage on shares of Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $380.56.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.